new med for type 2 diabetes, Avandia (rosiglitazone)

April 2000

There's now a new med for type 2 diabetes, Avandia (rosiglitazone)...from SmithKline Beecham.

It's the first "glitazone" to hit the market in Canada. Rezulin (troglitazone) was approved but never marketed in Canada. Another glitazone, Actos (pioglitazone), is due later this year.

These drugs reduce insulin resistance by stimulating the uptake of glucose into skeletal muscle cells...and decreasing glucose production in the liver.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

patients getting drug doses that are too high
Diabetes new med for type 2 diabetes, Avandia (rosiglitazone)
Diabetes alarming increase in type 2 diabetes in children and teens
Infectious Diseases Prevnar, the first pneumococcal vaccine that can be given to children under 2
Supplements news that vitamin C might increase the risk of vascular disease
Supplements huperzine A to improve memory and treat Alzheimer's
Thyroid Disorders many people might have heart disease related to UNDETECTED thyroid problems
Cerebyx (fosphenytoin injection)
low doses of gabapentin (Neurontin) for muscle cramps
Cardiology which drugs to use to prevent stroke
Cardiology patients DON'T need to stop low-dose ASA before ORAL surgery
Arava (Ah-RAY-va, leflunomide), a new disease-modifying drug for rheumatoid arthritis
Substance Use Disorder dextromethorphan abuse
Hypertension now urging physicians to avoid treating hypertension with alpha blockers

new med for type 2 diabetes, Avandia (rosiglitazone)

Practical advice for a better career, with unlimited access to CE

Table of Contents